Market Overview:

Blepharitis is a common eyelid condition characterized by inflammation and chronic flaking of the eyelid skin. It occurs due to various factors such as bacteria, dandruff, dry eyelids, and misdirected eyelashes. The key products used in blepharitis treatment include cleansers, warm compresses, lid scrubs, antibiotic ointments/drops, anti-inflammatory ointments, punctal plugs, and other eyelid hygiene products. These treatments aim to reduce inflammation, remove scaling/debris from eyelids, and prevent future recurrences. The growing incidence of chronic blepharitis along with the rising availability of customized treatments will boost the blepharitis treatment market over the forecast period.

The global Blepharitis Treatment Market is estimated to be valued at US$ 2.5 Bn in 2023 and is expected to exhibit a CAGR of 10.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Get more insights on this topic: https://www.coherentmarketinsights.com/market-insight/blepharitis-treatment-market-1761

Market key trends:

One of the major trends in the blepharitis treatment market is the rising adoption of minimally invasive procedures such as in-office ExpressTM KCL Express microblepharoexfoliation. This is a gentle, non-invasive eyecare procedure that removes oil glands and debris from the base of the eyelashes. It helps improve eyelid health and reduces inflammation associated with blepharitis. The procedure takes less than 15 minutes and provides lasting relief from symptoms for 3-6 months. The development of such innovative procedures is expected to drive the blepharitis treatment market during the forecast period.

Porter’s Analysis

Threat of new entrants: The threat of new entrants is low due to high capital requirements and established branding of existing players.

Bargaining power of buyers: The bargaining power of buyers is moderate due to availability of substitute treatment options.

Bargaining power of suppliers: The bargaining power of suppliers is low due to presence of many raw material suppliers.

Threat of new substitutes: The threat of new substitutes is moderate as alternative eye care products can be used for treatment.

Competitive rivalry: High due to presence of many established brands.

Key Takeaways

The global blepharitis treatment market is expected to witness high growth, exhibiting CAGR of 10% over the forecast period, due to increasing geriatric population coupled with rising awareness about eye disorders.

North America dominates the blepharitis treatment market owing to increasing prevalence of eye disorders due to changes in lifestyle and rising healthcare expenditure. However, Asia Pacific is expected to demonstrate highest growth rate due to growing geriatric population and developing healthcare infrastructure in the region.

Key players operating in the blepharitis treatment market are Scope Ophthalmic Ltd., NovaBay Pharmaceuticals Inc., Thea Pharmaceuticals Ltd., Perrigo Laboratories, InSite Vision Incorporated, Merck & Co., and Novartis AG. Scope Ophthalmic Ltd. dominates the market with its comprehensive product portfolio for blepharitis treatment.